---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-028366"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2024-05-31T23:59:59+00:00"
generated_at: "2026-06-01T07:11:48.075266+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immunocore reports Phase 1 brenetafusp data: 56% disease control in checkpoint pre-treated melanoma

## Summary
- Brenetafusp monotherapy in 47 late-line cutaneous melanoma patients showed 56% DCR (4 PR, 16 SD) and 4.2 months median PFS in PRAME+ patients.
- ctDNA molecular response in 42% of PRAME+ patients; trend for longer PFS/OS in molecular responders.
- Combination with pembrolizumab well tolerated; 4/7 evaluable patients achieved disease control including 1 ongoing PR.
- T cell fitness gene signature: high expression associated with 6-month median PFS and 69% DCR vs 2 months/42% for low.
- Phase 3 PRISM-MEL-301 trial (brenetafusp + nivolumab) enrolling first-line advanced melanoma patients.

## SEC filing metadata
- accession: 0001140361-24-028366
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2024-05-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000114036124028366/0001140361-24-028366-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000114036124028366/ef20030354_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-028366
- JSON: https://secwatch.observer/filing/0001140361-24-028366.json
- Plain text: https://secwatch.observer/filing/0001140361-24-028366.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.